Publications

5808 Results

Patient Comorbid Conditions and Cancer Clinical Trial Participation

Authors
J Unger;D Hershman;M Fleury;R Vaidya
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 6540); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Cancer Care Delivery

Causal modeling of CALGB 80405 identifies network drivers of metastatic colorectal cancer (CRC)

Authors
F Innocenti;H-J Lenz;J Meyerhardt;D Niedzwiecki;A Nixon;E O'Reilly;F-S Ou;A Venook;RK Das;L Furchtgott;D Cunha;K Rich;J Latourelle;D Wuest;B Hayete;I Khalil
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 3570); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A Randomized Phase II Study of Anti-Pd1 Antibody [Mk-3475 (Pembrolizumab)] Alone Versus Anti-Pd1 Antibody plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Authors
J Luke;S Chmura;J Salama;H Al-Hallaq;C Hsu;S Yom;M Kozloff;J Allred;P Munster;G Schwartz
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS9599); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
Year
2018
Research Committee(s)
Melanoma
Study Number(s)
CTSU/A091605

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)

Authors
G Abou-Alfa;Q Shi;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;R Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;RK Kelley;A Siegel;T Zemla;I El Dika;A Venook;M Bertagnolli;J Meyerhardt;EM O'Reilly
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr e16107);ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), publication only
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80802

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143)

Authors
L Harshman;M Puligandla;NB Haas;M Allaf;CG Drake;DF McDermott;S Signoretti;D Cella;RT Gupta;R Satish Bhatt;E Mendel Van Allen;T Choueiri;P Lara;A Kapoor;D Yick;C Heng;B Shuch;MAS Jewett;DJ George;M Dror Michaelson;MA Carducci
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS4597); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8143

A Randomized Study of Temozolomide or Temozolomide and Capecitabine in with Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211)

Authors
P Kunz;P Catalano;H Nimeiri;G Fisher;T Longacre;C Suarez;J Yao;M Kulke;A Hendifar;J Shanks;M Shah;M Zalupski;E Schmulbach;D Reidy-Lagunes;J Strosberg;P O'Dwyer;A Benson
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 4004; ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E2211

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial

Authors
A Bryce;Y Chen;G-F Liu;M Carducci;DF Jarrard;JA Garcia;R Dreicer;M Hussain;MA Eisenberger;M Kohli;NM Hahn;E Plimack;N Vogelzang;J Picus;R DiPaola;L Harshman;C Sweeney
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 5046); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL)
Year
2018
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Randomized trial of Irinotecan and Cetuximab (IC) verus Irinotecan, Cetuximab and Ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following Oxaliplatin and Bevacizumab based therapy: Results of E7208

Authors
H Hochster;P Catalano;EP Mitchell;DM Cohen;P O'Dwyer;B Faller;J Kortmansky;M O'Hara;S Kircher;J Lacy;HJ Lenz;U Verma;A Benson
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 3504); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E7208

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score

Authors
J Sparano;RJ Gray;W Wood;D Makower;T Lively;T Saphner;M Keane;HL Gomez;PS Reddy;T Goggins;I Mayer;D Toppmeyer;A Brufsky;M Goetz;D Hayes;C Dees;K Pritchard;CE Geyer;JA Olson;GW Sledge
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr LBA1); Annual Meeting (June 1- 5, 2018, Chicago, IL)
Year
2018
Research Committee(s)
Breast

Characterization and predictors of long term (= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients

Authors
M Friedlander;J Chan;J Java;DK Armstrong;M Markman;S Herzog;B Monk;F Backes;A Secord;A Bonebrake;P Rose;K Tewari;RS Mannel;S Lentz;M Geller;LJ Copeland
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 5556); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Gynecologic